Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.

Andrew W Roddam1, Naomi E Allen, Paul Appleby

  • 1Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, United Kingdom. andrew.roddam@ceu.ox.ac.uk

Annals of Internal Medicine
|October 8, 2008

Related Experiment Videos

View abstract on PubMed

Summary

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Insulin-like Growth Factors, Their Binding Proteins, And Prostate Cancer Risk: Analysis Of Individual Patient Data From 12 Prospective Studies.
    • This summary is machine-generated.

    Higher levels of insulin-like growth factor I (IGF-I) in the blood are linked to a moderately increased risk of developing prostate cancer. This finding is based on a large-scale analysis of participant data, highlighting IGF-I as a potential biomarker.

    Area of Science:

    • Endocrinology
    • Oncology
    • Epidemiology

    Background:

    • Previous studies suggest a link between insulin-like growth factors (IGFs), their binding proteins (IGFBPs), and prostate cancer risk.
    • However, published results have been inconsistent, necessitating further investigation.

    Purpose of the Study:

    • To comprehensively assess the association between circulating levels of IGFs and IGFBPs and the subsequent risk of prostate cancer.

    Main Methods:

    • A collaborative meta-analysis involving principal investigators from multiple studies.
    • Data from prospectively collected blood samples were pooled, including concentrations of IGF-I, IGF-II, IGFBP-II, and IGFBP-III.
    • Analysis included 3700 prostate cancer cases and 5200 control participants.

    Main Results:

    • Elevated serum IGF-I concentrations were significantly associated with an increased risk of prostate cancer (OR, 1.38 in the highest vs. lowest quintile; P < 0.001 for trend).
    • No significant association was found for IGF-II or IGFBP-II, though statistical power was limited.
    • IGF-I levels showed a stronger association with low-grade prostate cancer.

    Conclusions:

    • High circulating IGF-I concentrations are associated with a moderately increased risk for prostate cancer.
    • Limitations include single-sample measurements, varying laboratory methods, and incomplete disease staging information across studies.

    Related Experiment Videos